SecBot SecBot
Insider Cluster (5 insiders) ·Filed Nov 12, 2026

LYEL

Lyell Immunopharma, Inc.
BULLISH
Impact 6/10
Horizonweeks Processed4d 10h ago
Insider cluster: 3 insiders, $50.0M total
Actionable Insight ▲ Bullish

The $50M insider purchase by ARCH Venture Partners affiliates is a strong vote of confidence in Lyell's prospects, particularly given the timing with the Q3 earnings release and positive ronde-cel data. The executive sales are de minimis and likely personal liquidity. Monitor for any additional insider buying or updates on the BLA submission timeline for ronde-cel in H2 2027.

DirectionBullish
Confidencehigh
Horizonweeks

ronde-cel

▲ Bullish Named in this insider cluster
Impact
Phase
Phase 3
Time to market
Pivotal data from the PiNACLE trial is expected mid-2027, with a BLA submission planned for the second half of 2027. If approved, commercial launch would likely follow in 2028.
Next catalyst
None dated

What to watchThe next major catalyst is the ASH 2026 Annual Meeting (December 12-15, 2026), where updated data from the PiNACLE pivotal trial (3L+) and the Phase 1/2 second-line cohort will be presented in oral and poster sessions. Strong data could drive the stock toward analyst targets (mean $37.88), while disappointing durability or safety signals would pressure shares. The pivotal data readout expected in mid-2027 and BLA submission in H2 2027 are the longer-term binary events.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$14.30
T+0 close · Nov 12, 2026 · via day close
Latest settled
+2.45%
T+1 · $14.65
Vs SPY
+4.36%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $14.30entry
  2. T+1 · 20h ago +2.45%α +4.36% · $14.65
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Two 10% owner affiliates of ARCH Venture Partners purchased $50M in open-market shares on November 4, 2026, while three executives sold a combined $19K in open-market sales on November 10, 2026. The insider buying follows Lyell's Q3 2026 earnings release on November 4, which highlighted strong ronde-cel clinical data and an $80M private placement extending cash runway into 2028.

Key Financial Metrics

Direction
buying
Total Value
$50.0M
Insiders
5

Key Facts

  • ARCH Venture Partners IX and ARCH Venture Fund XIII each purchased 2.32M shares at $10.77, totaling $50M in open-market buys on November 4, 2026.
  • Three executives sold a combined $18,765 in open-market sales on November 10, 2026, at $15.93 per share.
  • The insider buying occurred on the same day as Lyell's Q3 2026 earnings release, which reported a GAAP net loss of $45.5M but highlighted strong ronde-cel clinical data and an $80M private placement.
  • The $50M insider purchase represents approximately 12.1% of Lyell's $412M market cap, a highly material signal.
  • The executive sales are trivial in size (0.005% of market cap) and likely unrelated to the ARCH purchases.

Financial Impact

Two 10% owner affiliates purchased $50M in open-market shares, representing 12.1% of market cap. Executive sales were $19K, immaterial.

ownership concentrationcash runway

Risk Factors

  • The company reported a widening GAAP net loss of $45.5M in Q3 2026, though the $80M private placement extends cash runway into 2028.
  • The stock price has risen from $10.77 (the ARCH purchase price) to $15.93 (the executive sale price) in six trading days, suggesting potential short-term volatility.
  • Ronde-cel BLA submission is not expected until H2 2027, leaving a long period without a near-term catalyst.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-LYEL-1794518040143

Track record

21 reports on LYEL

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +17.99% at T+60 after the Jun 8, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 13, 20263d ago S-3 Neutral 3/10 Entry $14.30 Now $14.65 +2.45% settles Nov 17
  2. Nov 12, 20264d ago Insider Cluster Bullish 6/10 Viewing Entry $14.30 to $14.65 Now $14.65 +2.45% ▲ +2.45% +4.36% vs SPY
  3. Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $16.86 to $15.64 Now $14.65 −13.11% ▼ −7.24% −6.88% vs SPY
  4. Nov 5, 202611d ago Insider Cluster Bullish 7/10 Entry $14.86 to $15.42 Now $14.65 −1.41% ▲ +3.77% +1.40% vs SPY
  5. Nov 4, 202612d ago 8-K Neutral 4/10 No price data
  6. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.00 to $14.86 Now $14.65 −2.33% ▼ −0.93% −1.25% vs SPY
  7. Nov 4, 202612d ago 8-K Bearish 5/10 Entry $15.43 to $15.00 Now $14.65 +5.06% ▲ +2.79% −1.62% vs SPY
  8. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.43 to $15.00 Now $14.65 −5.06% ▼ −2.79% +1.62% vs SPY
  9. Aug 25, 202611w ago Insider Cluster Neutral 4/10 Entry $14.80 to $14.61 Now $14.65 −1.01% ▼ −1.28% −1.94% vs SPY
  10. Jul 22, 202616w ago EFFECT Neutral 4/10 Entry $12.84 to $12.78 Now $14.65 +14.10% ▼ −0.47% +0.77% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026